Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4001014 | 0.86 | KDM4E (0.30) | ALDH1A1 | |
| SCHEMBL3999804 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TRPA1 | |
| SCHEMBL3997058 | 0.71 | ALDH1A1 (0.42) | ALDH1A1TRPA1 | |
| SCHEMBL4005652 | 0.70 | ALDH1A1 (0.41) | ALDH1A1TRPA1 | |
| Hydrochloric Acid SCHEMBL7719973 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL8359905 | 0.68 | CHKA (0.30) | — | |
| SCHEMBL6231239 | 0.67 | — | — | |
| SCHEMBL6236063 | 0.67 | — | — | |
| SCHEMBL4135268 | 0.66 | FAAH (0.37) | ALDH1A1TRPA1 | |
| SCHEMBL3997677 | 0.65 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556417-B1 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2009-06-10 | — | — | EP | disclosed |
| US-7358381-B2 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | BASELL POLYOLEFINE GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | EQUISTAR CHEMICALS, LP | 2006-05-25 | — | — | US | disclosed |
| EP-1556417-A2 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | Basell Polyolefine GmbH (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037834-A2 | RACEMOSELECTIVE PREPARATION OF BRIDGED METALLOCENE COMPLEXES HAVING UNSUBSTITUTED OR 2-SUBSTITUTED INDENYL LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111527-A1 | Racemoselective preparation of bridged metallocene complexes having unsubstituted or 2-substituted indenyl ligands | ITPA, IMPA1, INTS9 | ALDH1A1 888/4885TRPA1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.